Healthcare News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Healthcare Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HealthcareNewsGeneric Drug Facilities, Sites and Organization Lists
Generic Drug Facilities, Sites and Organization Lists
Healthcare

Generic Drug Facilities, Sites and Organization Lists

•February 13, 2026
0
FDA – U.S. Food & Drug Administration (RSS Feeds)
FDA – U.S. Food & Drug Administration (RSS Feeds)•Feb 13, 2026

Why It Matters

Transparent facility data helps regulators, manufacturers, and investors monitor compliance and supply‑chain risks, strengthening confidence in the generic drug market.

Key Takeaways

  • •FDA releases annual facility lists FY2014‑2026.
  • •Data enhances transparency of generic drug supply chain.
  • •Stakeholders can assess compliance and risk exposure.
  • •Growing number of facilities signals market expansion.
  • •Regulators use lists for targeted inspections.

Pulse Analysis

The Food and Drug Administration’s yearly compilations of self‑identified generic drug facilities serve as a cornerstone for market transparency. By cataloguing manufacturers, contract producers, and related sites, the FDA creates a searchable repository that policymakers and industry analysts can leverage to gauge the breadth of the generic ecosystem. This systematic disclosure aligns with broader regulatory trends that prioritize data‑driven oversight, enabling faster identification of potential quality gaps before they affect patients.

Analyzing the FY2014‑2026 series reveals a steady increase in the number of listed entities, reflecting both the growth of the generic market and the diversification of supply chains. As more firms enter the space, the risk profile becomes more complex, prompting manufacturers to adopt rigorous vendor‑management programs. Investors and insurers also benefit, using the data to model supply‑chain resilience and anticipate pricing pressures. The publicly available lists thus act as an early‑warning system, supporting proactive risk mitigation across the value chain.

For the business community, the implications are twofold. First, compliance teams can cross‑reference the FDA’s lists with internal supplier databases to ensure all partners meet regulatory expectations. Second, the visibility into facility locations and ownership structures aids strategic decisions such as mergers, acquisitions, or geographic diversification. As the FDA continues to refine its reporting mechanisms, stakeholders can expect even richer datasets, further embedding transparency into the generic drug industry’s operational fabric.

Generic Drug Facilities, Sites and Organization Lists

Self‑Identified Generic Drug Facilities, Sites and Organizations (FY 2014 – 2026)

  • FY 2026: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/186512/download?attachment

  • FY 2025: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/178556/download?attachment

  • FY 2024: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/167716/download?attachment

  • FY 2023: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/158444/download?attachment

  • FY 2022: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/148286/download?attachment

  • FY 2021: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/137664/download?attachment

  • FY 2020: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/124398/download?attachment

  • FY 2019: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/113448/download

  • FY 2018: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/98125/download

  • FY 2017: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/105210/download

  • FY 2016: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/91532/download

  • FY 2015: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/145629/download?attachment

  • FY 2014: Self‑Identified Generic Drug Facilities, Sites and Organizations

    http://www.fda.gov/media/145630/download?attachment

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...